We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.40 | 78,622 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 3.30 | 3.50 | 3.40 | 3.40 | 3.40 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.9M | -2.6M | -0.0272 | -1.25 | 3.24M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:58 | O | 28 | 3.4999 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 22/7/2024 | 12:54 | UK RNS | Fusion Antibodies PLC Director/PDMR Shareholding |
| 18/7/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Launch of New Interactive Investor Hub |
| 04/7/2024 | 13:33 | ALNC |  TRADING UPDATES: itim signs contract; Tekmar renews banking facilities |
| 04/7/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Trading update |
| 23/5/2024 | 21:08 | ALNC | TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact |
| 23/5/2024 | 07:00 | UK RNS | Fusion Antibodies PLC New contract with existing client |
| 02/5/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Investor presentation |
| 30/4/2024 | 19:54 | ALNC | EARNINGS AND TRADING: Software Circle & Beximco report higher revenue |
| 30/4/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Year-end trading statement |
| 16/4/2024 | 07:00 | UK RNS | Fusion Antibodies PLC Change of auditor |
Fusion Antibodies (FAB) Share Charts1 Year Fusion Antibodies Chart |
|
1 Month Fusion Antibodies Chart |
Intraday Fusion Antibodies Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 23/7/2024 | 15:23 | ☆ Fusion Antibodies: from discovery to Clinical supply ☆ | 4,010 |
| 28/11/2023 | 16:25 | NEW FAB Fusion Antibodies The Next AVCT | 64 |
| 18/9/2020 | 15:23 | Fusion Antibody II | 51 |
| 17/9/2020 | 09:25 | COVID. RAPID PROGRESS MADE. Ј3M RAISED | 58 |
| 08/2/2012 | 21:34 | Fabio Capello Resigns....... | 9 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-07-26 15:30:00 | 3.50 | 28 | 0.98 | O |
| 2024-07-26 15:29:44 | 3.50 | 28 | 0.98 | O |
| 2024-07-26 14:39:32 | 3.50 | 28 | 0.98 | O |
| 2024-07-26 11:42:58 | 3.50 | 28 | 0.98 | O |
| 2024-07-26 11:38:33 | 3.49 | 50,000 | 1,745.00 | O |
| Top Posts |
|---|
Posted at 26/7/2024 09:20 by Fusion Antibodies Daily Update Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.40p.Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3,242,429. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.25. This morning FAB shares opened at 3.40p |
Posted at 23/7/2024 15:00 by thiopia 04/07/2024 Fusion Antibodies PLC Trading update18/07/2024 Fusion Antibodies PLC Launch of New Interactive Investor Hub 22/07/2024 Fusion Antibodies PLC Director/PDMR Shareholding Think they might be trying to tell us something? Something about business being #FAB maybe ? |
Posted at 03/7/2024 12:34 by jaknife soultrading,"Taken from company itself and broker notes. So factual based on info we currently have" If that's taken from a broker's note then that broker is either incompetent or bent (and has been paid to write optimistic nonsense). Let's go through the numbers slowly: 1. The recent trend of revenue performance is: 2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024E £1.14m 2. The gross margin in the year to 31 March 2023 was 19.8% , let's assume that it comes in at a round 20% for the year to 31 March 2025. 3. Historic admin costs are in the ball park of £3m per annum. 4. Based on these numbers, this means that FAB needs to get to a revenue of c. £15m in order to just break even. Ie: (£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000 -------Profit for the period £ 0 You don't need to do anything more detailed than this to understand that: A. FAB need to get to a revenue of £15m in 2025 just to breakeven. B. IF FAB only get to a revenue of £7.5m then they will lose/burn £1.5m. Given the recent revenue trend and the lack of RNSs claiming huge contract wins then we can all safely assume that FAB is on target to make revenues materially less than £7.5m. Somewhere in the £2m range is probably optimistic. And, on that basis, FAB is going to run out of cash before Christmas! JakNife |
Posted at 03/7/2024 10:57 by jaknife soultrading,What complete garbage. For example: "They are fully funded into 2025 and like to be cash neutral to positive this year." Post 3,931 shows the fundamental numbers, FAB need to achieve revenue of c. £15.0 to reach breakeven when last year the revenue was only £1.14m and the biggest brag that the company has so far is that their have "an orderbook of £0.75m". There is not a hope in hell that FAB will be cash neutral this year. At current cash burn rates the cash will run out well before Christmas! JakNife |
Posted at 03/7/2024 10:32 by soultrading My summary of the situation THE PASTI think you are right, the way I see it is that the company went through a tough period, caused by being too focused on a particular area, and client base. This focused client base was highly dependent on a constant flow of venture capital. When VC dropped off across the board, the smaller companies (fusions clients) had to put projects on hold and therefore so did fusion.This put fusion in a difficult place and led to a need for fusion to raise capital during very unfavourable market conditions.The combination of these two issues caused a massive fall in share price and rightly so, which was not good for existing shareholders.SURVIVE MODEThe board addressed these issues by reducing out goings, headcount and the directors agreed to be paid in shares.They also diversified their client base to include venture capital but also blue chip organisations, research clientele, and branched into other areas such as veterinary. They also have started a royalty program to achieve on going working capital.This was a smart and needed move as it eliminates the past from reoccurring. THRIVE MODETo achieve this the company has been heavily promoting itself in the industry and signed with huge companies and organisations some of which are in the billionaire bracket as a result.The smart speculation is that one very large antibody company has also signed a test contract with the purpose of branching into the therapeutic area. This is a gateway which could open many partnerships for both companies.And of course having signed with USA Cancer research to validate their OPTIMAL at zero cost.INVESTMENT CASEThis is a recovery trade at these levels. But one that has been derisked heavily now and provides an almost unbelievable opportunity to buy cheap stock, The current share price is not attributing any value to fusions, tech, Intellectual property or the changes the company have made in their outgoings, cash position, royalties, grants, or stronger portfolio base.They are fully funded into 2025 and like to be cash neutral to positive this year. They have a working pipeline of sales which is converting to revenues and growing fast. The board are seeing a marked improvement across the sector and from the recent interviews it suggests the company has already turned a corner and are doing well.I don't think opportunities like this come along very often and it is certainly a buy and hold trade which could lead to a huge increase in value, |
Posted at 02/7/2024 20:10 by jaknife troutisout,I have DM'd you the Allenby broker forecasts. But my apologies my wording was imprecise, "in 20024" should be "in the year to 31 Dec 2024", there are no forecasts available beyond that. What words/numbers in the 30 April 2024 Year-end trading statement make you think that "FAB have turned a corner"? I note: "Significant increase in sales pipeline opportunities during H2 FY2024, with an orderbook at 31 March 2024 of £0.75m, representing 65 per cent. of total FY2024 unaudited revenues" However: 1. This was the first time that FAB published a number for their pipeline so it's impossible to tell if this represents an improvement on the prior period and hence evidence of having "turned a corner"? 2. The gross margin in the year to 31 March 2023 was 19.8% and admin costs are in the ball park of £3m per annum. That means that FAB has to get to a revenue of c. £15m in order to just break even. Ie: (£k)Revenue £15,000Cost of sales £12,000Gross profit £ 3,000 (20%)Admin expenses £ 3,000Profit for the period £ 0 I have assumed a 20% gross profit margin to keep the numbers simple. If FAB don't get to a revenue of £15m then they will make a loss in the year to 31 March 2025. Furthermore, if FAB don't get to half of that revenue number (£7,500k) then FAB will burn through their current cash and need to raise funds again. What forecast full-year revenue for 2025 do you infer from the 30 April 2024 Year-end trading statement? JakNife |
Posted at 02/7/2024 11:47 by jaknife bobaxe1,"Oversold company Turned a corner Should re rate" Do you have anything to demonstrate that FAB has "turned a corner"? It's just that I noted here a while ago that the recent trend of revenue performance is: 2020 £4.17m2021 £4.80m2022 £2.90m2023 £1.58m2024E £1.14m So current forecasts for 2024 are that revenue will be 28% *DOWN* on 2023 revenue, continuing a negative trend. Those same forecasts are for continued losses in 2024. Have I missed an RNS that demonstrates that FAB has "turned a corner"? Are forecasts for 2025 materially higher? Is 2025 finally going to be a profitable year? Where is the objective evidence please? JakNife |
Posted at 23/6/2024 12:17 by soultrading THE PASTI think you are right, the way I see it is that the company went through a tough period, caused by being too focused on a particular area, and client base. This focused client base was highly dependent on a constant flow of venture capital. When VC dropped off across the board, the smaller companies (fusions clients) had to put projects on hold and therefore so did fusion.This put fusion in a difficult place and led to a need for fusion to raise capital during very unfavourable market conditions.The combination of these two issues caused a massive fall in share price and rightly so, which was not good for existing shareholders.SURVIVE MODEThe board addressed these issues by reducing out goings, headcount and the directors agreed to be paid in shares.They also diversified their client base to include venture capital but also blue chip organisations, research clientele, and branched into other areas such as veterinary. They also have started a royalty program to achieve on going working capital.This was a smart and needed move as it eliminates the past from reoccurring. THRIVE MODETo achieve this the company has been heavily promoting itself in the industry and signed with huge companies and organisations some of which are in the billionaire bracket as a result.The smart speculation is that one very large antibody company has also signed a test contract with the purpose of branching into the therapeutic area. This is a gateway which could open many partnerships for both companies.And of course having signed with USA Cancer research to validate their OPTIMAL at zero cost.INVESTMENT CASEThis is a recovery trade at these levels. But one that has been derisked heavily now and provides an almost unbelievable opportunity to buy cheap stock, The current share price is not attributing any value to fusions, tech, Intellectual property or the changes the company have made in their outgoings, cash position, royalties, grants, or stronger portfolio base.They are fully funded into 2025 and like to be cash neutral to positive this year. They have a working pipeline of sales which is converting to revenues and growing fast. The board are seeing a marked improvement across the sector and from the recent interviews it suggests the company has already turned a corner and are doing well.I don't think opportunities like this come along very often and it is certainly a buy and hold trade which could lead to a huge increase in value, |
Posted at 23/5/2024 11:51 by paulisi I do see signs of potential.New contracts are coming in, even if they are small.However, if this share price is to jump it needs:At least one of the contracts to commercialise and generate revenues via royaltiesMore contracts, to avoid having to ask the market for more cash.At the moment, it is a very speculative share. |
Posted at 27/2/2024 10:31 by troutisout "Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announced it has received a first purchase order under the master services agreement (MSA) with a leading diagnostics company details of which were announced on 14 February 2024. FAB said reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies’ technologies and capabilities. In this case it is the generation of antibodies in diagnostics products.Comment: It could be argued that fundamentally FAB is now on track as a recovery situation, with the purchase order and recent funding. Only a rise in the share price is missing." |
Posted at 06/12/2023 14:31 by daniel Don't listen to Jaknife. He works for certain brokerage firms seeking to undermine companies by depressing the share prices; in the hope of getting cheap shares after front-selling. Check out his history with many companies. He is a scammer that manipulates unseasoned PI's.You can see him targeting fundraising but totally ignoring the OptiMal Collaboration agreement. That's the usual pattern. But you wander where the donkey had been when the share price was much higher. I am looking to invest in this company, but his presence is depressant to the share price. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
